QQ客服 官方微博 反馈留言

浏览/检索结果: 共38条，第1-10条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer 期刊论文 2019, 卷号: 6, 期号: 19, 页码: 1900721 作者:  Lu Jun;  Zhong Hua;  Wu Jun;  Chu Tianqing;  Zhang Lele 收藏  |  浏览/下载：13/0  |  提交时间：2020/01/03 anlotinib  liquid biopsies  non‐small cell lung cancer (NSCLC)  stratification  tumor mutation index   China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy 期刊论文 2019, 卷号: 39, 期号: 1, 页码: 36 作者:  Zhou, Ming;  Chen, Xiaoyuan;  Zhang, Hong;  Xia, Lin;  Tong, Xin 收藏  |  浏览/下载：29/0  |  提交时间：2020/01/03 Advanced non-small cell lung cancer  Anlotinib  Anti-angiogenesis  Epidermal growth factor receptor  Activating anaplastic lymphoma kinase  Adverse drug reaction  National Medical Products Administration   Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303 期刊论文 2019, 卷号: 10, 期号: 3, 页码: 551-556 作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：13/0  |  提交时间：2020/01/03 Adverse event  anlotinib  multi-target tyrosine kinase inhibitor  non-small cell lung cancer   Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial 期刊论文 2019, 卷号: 24, 期号: 8, 页码: E702-E708 作者:  Zhou, Ai-Ping;  Bai, Yuxian;  Song, Yan;  Luo, Hong;  Ren, Xiu-Bao 收藏  |  浏览/下载：18/0  |  提交时间：2020/01/03 Anlotinib  Metastatic renal cell cancer  Phase II clinical trial   Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer 期刊论文 2018, 卷号: 28, 期号: 11, 页码: 1455-1461 作者:  Sun, Yongkun;  Du, Feng;  Gao, Ming;  Ji, Qinghai;  Li, Zhendong 收藏  |  浏览/下载：12/0  |  提交时间：2020/01/03 anlotinib  medullary thyroid carcinoma  clinical trial   Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文 2018, 卷号: 4, 期号: 11, 页码: 1569-1575 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03 Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer 期刊论文 2018, 卷号: 122, 页码: 32-37 作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03 Anlotinib  Non-small cell lung cancer  Quality of life   Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma 期刊论文 2018, 卷号: 24, 期号: 21, 页码: 5233-5238 作者:  Chi, Yihebali;  Fang, Zhiwei;  Hong, Xiaonan;  Yao, Yang;  Sun, Ping 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03 Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) 期刊论文 2018, 卷号: 118, 期号: 5, 页码: 654-661 作者:  Han, Baohui;  Li, Kai;  Zhao, Yizhuo;  Li, Baolan;  Cheng, Ying 收藏  |  浏览/下载：9/0  |  提交时间：2020/01/03 non-small-cell lung cancer  multitarget  tyrosine kinase inhibitor  anlotinib  third line   Evaluation of hypertension and hand-foot syndrome as markers of anlotinib efficacy in advanced soft tissue sarcoma 期刊论文 2018, 卷号: 29, 页码: 587-587 作者:  Fang, Z.;  Chi, Y.;  Yao, Y.;  Wang, S.;  Huang, G. 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03